Xu Haonan, Guo Wenxin, Chou Oscar Hou In, Tse Gary, Li Guangping, Liu Tong, Fu Huaying
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Department of Medicine, Division of Clinical Pharmacology and Therapeutics, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Catheter Cardiovasc Interv. 2025 Aug;106(2):1263-1272. doi: 10.1002/ccd.31678. Epub 2025 Jun 9.
Patients undergoing complex high-risk percutaneous coronary interventions (CHIP) are prone to hemodynamic instability, and the optimal mechanical circulatory support (MCS) strategy for this population remains unclear.
This systematic review and network meta-analysis aimed to compare the short-term safety and efficacy of various MCS strategies in CHIP.
We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library for studies comparing different MCS strategies in CHIP patients with short-term endpoints. The primary efficacy outcome was in-hospital or 30-day mortality. Safety outcomes included MCS-related complications, specifically bleeding and stroke. The MCS strategies evaluated were intra-aortic balloon pump (IABP), veno-arterial extracorporeal membrane oxygenation (VA-ECMO), IMPELLA, VA-ECMO + IABP, and VA-ECMO + IMPELLA (ECPELLA). A random-effects Bayesian network meta-analysis was performed, integrating both direct and indirect comparisons.
Twelve studies involving a total of 75,274 patients were included. Both IABP (OR: 0.33; 95% CI: 0.13-0.91) and IMPELLA (OR: 0.44; 95% CI: 0.21-0.96) were associated with significantly lower short-term mortality compared to VA-ECMO. No significant differences were observed among other strategies. Rank probability analysis suggested that IABP had the highest probability of being the most effective strategy for reducing short-term mortality. Regarding safety outcomes, IABP was associated with a significantly lower bleeding risk compared to VA-ECMO (OR: 0.18; 95% CI: 0.04-0.82), VA-ECMO + IABP (OR: 0.18; 95% CI: 0.03-0.87), ECPELLA (OR: 0.12; 95% CI: 0.02-0.70), and IMPELLA (OR: 0.21; 95% CI: 0.05-0.75), with no significant difference in stroke risk across strategies.
Among available MCS strategies for CHIP patients, IABP appears to be associated with improved short-term survival and a lower risk of bleeding, without an increased risk of stroke. These findings support IABP as a potentially preferable support option, warranting further validation in prospective clinical trials.
接受复杂高危经皮冠状动脉介入治疗(CHIP)的患者容易出现血流动力学不稳定,而针对该人群的最佳机械循环支持(MCS)策略仍不明确。
本系统评价和网状Meta分析旨在比较各种MCS策略在CHIP患者中的短期安全性和有效性。
我们系统检索了PubMed、科学网、Embase和考克兰图书馆,以查找比较不同MCS策略在CHIP患者中短期终点的研究。主要疗效结局为住院期间或30天死亡率。安全性结局包括与MCS相关的并发症,特别是出血和中风。评估的MCS策略包括主动脉内球囊反搏(IABP)、静脉-动脉体外膜肺氧合(VA-ECMO)、Impella、VA-ECMO+IABP和VA-ECMO+Impella(ECPELLA)。进行了随机效应贝叶斯网状Meta分析,整合了直接和间接比较。
纳入了12项研究,共75274例患者。与VA-ECMO相比,IABP(OR:0.33;95%CI:0.13-0.91)和Impella(OR:0.44;95%CI:0.21-0.96)均与显著降低的短期死亡率相关。其他策略之间未观察到显著差异。排序概率分析表明,IABP是降低短期死亡率最有效策略的可能性最高。关于安全性结局,与VA-ECMO(OR:0.18;95%CI:0.04-0.82)、VA-ECMO+IABP(OR:0.18;95%CI:0.03-0.87)、ECPELLA(OR:0.12;95%CI:0.02-0.70)和Impella(OR:0.21;95%CI:0.05-0.75)相比,IABP的出血风险显著更低,各策略的中风风险无显著差异。
在CHIP患者可用的MCS策略中,IABP似乎与短期生存率提高和出血风险降低相关,且中风风险未增加。这些发现支持IABP作为一种潜在的更优支持选择,有待在前瞻性临床试验中进一步验证。